

NIGERIA PNEUMOCOCCAL VACCINE SUPPORT

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Nigeria			
2. Grant Number: 1315-NGA-12b-X / 13-NGA-08a-Y			
3. Date of Decision Letter: 24 September 2014			
4. Date of the Partnership Framework Agreement: 9 January 2014			
5. Programme Title: NVS, Pneumococcal Routine			
6. Vaccine type: Pneumococcal			
7. Requested product presentation and formulation of vaccine: Pneumococcal (PCV10), 2 dose(s) per vial , LIQUID			
8. Programme Duration¹: 2014-2015			
9. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement):			
	2014	2015*	Total ²
Programme Budget (US\$)	US\$20,398,000	US\$49,858,500	US\$70,256,500
* 2015 values are subject to change, pending review by the High Level Review Panel of the newly submitted figures within the 2013 Annual Progress Report.			
10. Vaccine Introduction Grant: US\$5,602,500 payable up to six months before vaccine introduction.			
11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):³ [The Annual Amount for 2014 has been amended].			
Type of supplies to be purchased with GAVI funds in each year	2014		
Number of Pneumococcal vaccines doses	3,774,400		
Number of AD syringes	3,822,700		
Number of safety boxes	42,075		
Annual Amounts (US\$)	US\$20,398,000		

¹ This is the entire duration of the programme.

² This is the total amount endorsed by GAVI for the entire duration of the programme. This should be equal to the total of all sums in the table.

³ This is the amount that GAVI has approved.

12. Procurement agency: UNICEF.																				
13. Self-procurement: Not applicable.																				
<p>14. Co-financing obligations: Reference code: 1315-NGA-12b-X-C According to the Co-Financing Policy, the Country falls within the Intermediate group. The following table summarises the Co-Financing Payment(s) and quantity of supply that will be procured with such funds in the relevant year.</p> <table border="1"> <thead> <tr> <th>Type of supplies to be purchased with Country funds in each year</th> <th>2014</th> <th>2015*</th> </tr> </thead> <tbody> <tr> <td>Number of vaccine doses</td> <td>225,600</td> <td>645,200</td> </tr> <tr> <td>Number of AD syringes</td> <td>228,500</td> <td></td> </tr> <tr> <td>Number of safety boxes</td> <td>2,525</td> <td></td> </tr> <tr> <td>Value of vaccine doses (US\$)</td> <td>US\$764,689</td> <td></td> </tr> <tr> <td>Total Co-Financing Payments (US\$) (including freight)</td> <td>US\$800,000</td> <td>US\$2,275,000</td> </tr> </tbody> </table> <p>* 2015 values are subject to change, following review by the High Level Review Panel of the newly submitted figures within the 2013 Annual Progress Report and the application of the new co-financing grouping. .</p>			Type of supplies to be purchased with Country funds in each year	2014	2015*	Number of vaccine doses	225,600	645,200	Number of AD syringes	228,500		Number of safety boxes	2,525		Value of vaccine doses (US\$)	US\$764,689		Total Co-Financing Payments (US\$) (including freight)	US\$800,000	US\$2,275,000
Type of supplies to be purchased with Country funds in each year	2014	2015*																		
Number of vaccine doses	225,600	645,200																		
Number of AD syringes	228,500																			
Number of safety boxes	2,525																			
Value of vaccine doses (US\$)	US\$764,689																			
Total Co-Financing Payments (US\$) (including freight)	US\$800,000	US\$2,275,000																		
<p>15. Operational support for campaigns: Not applicable.</p> <table border="1"> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> </table>																				
<p>16. Additional documents to be delivered for future disbursements:</p> <table border="1"> <tr> <td>Reports, documents and other deliverables</td> <td>Due dates</td> </tr> <tr> <td>Annual Progress Report or equivalent</td> <td>To be agreed with GAVI Secretariat</td> </tr> </table>			Reports, documents and other deliverables	Due dates	Annual Progress Report or equivalent	To be agreed with GAVI Secretariat														
Reports, documents and other deliverables	Due dates																			
Annual Progress Report or equivalent	To be agreed with GAVI Secretariat																			
17. Financial Clarifications: Not applicable.																				
18. Other conditions: Not applicable.																				

On behalf of the GAVI Alliance



Hind Khatib-Othman
Managing Director, Country Programmes

24 September 2014